ArticleAnticancer research2010
Unique SNP in CD44 intron 1 and its role in breast cancer development.
Article in Anticancer research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Impact of CD44 genetic variants on clinicopathological characteristics of uterine cervical cancer patients.International journal of medical sciences · 2024Article
- Genetic Polymorphism in FSCN1 rs3801004 C/G and CD44 rs353639 A/C, as Prognostic Factor in Egyptian Breast Cancer Patients.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Association of CD44 polymorphisms and susceptibility to HBV-related hepatocellular carcinoma in the Chinese population.Journal of clinical laboratory analysis · 2019Article
- Association of Single-Nucleotide Polymorphisms of CD44 Gene with Susceptibility to Breast Cancer in Chinese Women.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Unique CD44 intronic SNP is associated with tumor grade in breast cancer: a case control study and in silico analysis.Cancer cell international · 2018Article
- The peptidylglycine-α-amidating monooxygenase (PAM) gene rs13175330 A>G polymorphism is associated with hypertension in a Korean population.Human genomics · 2017Article
- Article
- Associations of five polymorphisms in the CD44 gene with cancer susceptibility in Asians.Scientific reports · 2016Article
- Effect of CD44 gene polymorphisms on risk of transitional cell carcinoma of the urinary bladder in Taiwan.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- CXM: a new tool for mapping breast cancer risk in the tumor microenvironment.Cancer research · 2014Article
- Changes in DNA methylation patterns and repetitive sequences in blood lymphocytes of aged horses.Age (Dordrecht, Netherlands) · 2014Article
- CD44 gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathologic features.BioMed research international · 2014Article
- CD44 gene polymorphisms and environmental factors on oral cancer susceptibility in Taiwan.PloS one · 2014Article
- CD44 gene polymorphisms in breast cancer risk and prognosis: a study in North Indian population.PloS one · 2013Article
- Implications of single nucleotide polymorphisms in CD44 exon 2 for risk of breast cancer.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2011Article
- Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma.International journal of cancer · 2011Article
- Concurrent Reduced Expression of ContiguousCancer genomics & proteomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
In the current study, we investigated if CD44 polymorphisms are associated with increased susceptibility to breast cancer. Direct nucleotide sequencing analysis identified a novel and unique single nucleotide polymorphism (SNP, designated as CD44 Ex2+14 A>G) in the CD44 intron 1 region in 84% of breast cancer patients, which was significantly higher than that seen in normal donors. Moreover, the breast cancer patients with homozygous unique SNP in CD44 intron 1 had breast cancer at earlier ages, larger tumor burden, more regional lymph node metastases at the time of diagnosis, and higher cancer recurrence rate. There was a strong association between the unique SNP in CD44 intron 1 and CD44 expression on peripheral blood mononuclear cells. Our results suggest that CD44 polymorphism is associated with breast cancer development, and CD44 polymorphism analysis may be effectively used in the risk assessment, prediction, prevention, diagnosis and genetic epidemiological analysis of breast cancer.
Indexed as
Identifiers
20530438PMC4138972W1812133991What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.